Hepatotoxicity of herbal medicines, vitamins, and natural hepatotoxins

Drug-Induced Liver Disease, Second Edition

Volumn , Issue , 2007, Pages 733-754

  Liu, Lawrence U ^a   Schiano, Thomas D ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 46349093708     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (133)

1. http://nccam.nih.gov/news/camsurvey_fs1.htm (Accessed October 2005).
2. Ernst E. Harmless herbs? A review of the recent literature. Am J Med 1998; 104(2):170-8.
3. Willett KL, Roth RA, Walker L. Workshop overview: hepatotoxicity assessment for botanical dietary supplements. Toxicol Sci 2004; 79(1):4-9.
4. Kaplowitz N. Hepatotoxicity of herbal remedies: insights into the intricacies of plant-animal welfare and cell death. Gastroenterology 1997; 113(4):1408-12.
5. Larrey D. Hepatotoxicity of herbal remedies. J Hepatol 1997; 26(Suppl. 1):47-51.
6. Fogden E, Neuberger J. Alternative medicines and the liver. Liver 2003; 23(4):213-20.
7. Seeff LB, Lindsay KL, Bacon BR, et al. Complementary and alternative medicine in chronic liver disease. Hepatology 2001; 34(3):595-603.
8. Stedman C. Herbal hepatotoxicity. Semin Liver Dis 2002; 22(2):195-206.
9. Ernst E. The risk-benefit profile of commonly used herbal therapies: ginkgo, St. John’s wort, ginseng, echinacea, saw palmetto, and kava. Ann Intern Med 2002; 136(1):42-53.
10. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 2000; 280(18):1569-75.
11. Marcus DM, Grollman AP. Botanical medicines-the need for new regulations. N Engl J Med 2002; 347(25):2073-6.
12. Carlsson C. Herbs and hepatitis. Lancet 1990; 2(8722):1068.
13. Neff GW, O’Brien C, Montalbano M, et al. Consumption of dietary supplements in a liver transplant population. Liver Transpl 2004; 10(7):881-5.
14. Phillips LG, Nichols MH, King WD. Herbs and HIV. South Med J 1995; 88(9):911-3.
15. Nahin RL, Straus SE. Research into complementary and alternative medicine: problems and potential. Br Med J 2001; 322(7279):161-4.
16. Zimmerman HJ, Ishak KG. General aspects of drug-induced liver disease. Gastroenterol Clin North Am 1995; 24(4):739-57.
17. Zimmerman HJ, Lewis JH. Chemical- and toxin-induced hepatotoxicity. Gastroenterol Clin North Am 1995; 24(4):1027-45.
18. Kumar NB, Allen K, Bell H. Perioperative herbal supplement use in cancer patients: potential implications and recommendations for presurgical screening. Cancer Control 2005; 12(3):149-57.
19. Chitturi S, Farrell GC. Herbal hepatotoxicity: an expanding but poorly defined problem. J Gastroenterol Hepatol 2000; 15(10):1093-9.
20. Estes JD, Stolpman D, Olyaei A, et al. High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure. Arch Surg 2003; 138(8):852-8.
21. McGee J, Patrick RS, Wood CB, et al. A case of veno-occlusive disease of the liver in Britain associated with herbal tea consumption. J Clin Pathol 1976; 29(9):788-94.
22. Tandon HD, Tandon BN, Ramalingaswami V. Epidemic of toxic hepatitis in India of possible mycotoxic origin. Arch Pathol Lab Med 1978; 102(7):372-6.
23. Abebe W. Herbal medication: potential for adverse interactions with analgesic drugs. J Clin Pharm Ther 2002; 27(6):391-401.
24. Stickel F, Seitz HK. The efficacy and safety of comfrey. Public Health Nutr 2000; 3(4A):501-8.
25. Bras G, Jelliffe DB, Stuart KL. Veno-occlusive disease of liver with nonportal type of cirrhosis occurring in Jamaica. Arch Path 1954; 57(4):285-300.
26. Valla D, Benhamou JP. Drug-induced vascular and sinusoidal lesions of the liver. Clin Gastroenterol 1988; 2(2):481-500.
27. Ridker PM, Ohkuma S, McDermott WV, et al. Hepatic venoocclusive disease associated with the consumption of pyrrolizidine-containing dietary supplements. Gastroenterology 1985; 88(4):1050-4.
28. DeLeve L, Wang X, Kuhlenkamp J, et al. Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic venoocclusive disease. Hepatology 1996; 23(3):589-99.
29. Huxtable RJ. New aspects of the toxicology and pharmacology of pyrrolizidine alkaloids. Mol Pharmacol 1979; 10(3):159-67.
30. Mattocks AR. Toxicity of pyrrolizidine alkaloids. Nature 1968; 217(5130):723-8.
31. GordonDW, Rosenthal G, Hart J, et al. Chaparral ingestion. The broadening spectrum of liver injury caused by herbal mediations. JAMA 1995; 273(6):489-90.
32. Kassler WJ, Blanc P, Greenblatt R. The use of medicinal herbs by human immunodeficiency virusinfected patients. Arch Intern Med 1991; 151(11):2281-8.
33. Sheikh NM, Philen RM, Love LA. Chaparral-associated hepatotoxicity. Arch Intern Med 1997; 157(8):913-9.
34. Kauma H, Koskela R, Mäkisalo H, et al. Toxic acute hepatitis and hepatic fibrosis after consumption of chaparral tablets. Scand J Gastroenterol 2004; 39(11):1168-71.
35. Singh YN, Singh NN. Therapeutic potential of kava in the treatment of anxiety disorders. CNS Drugs 2002; 16(11):731-43.
36. Singh YN. Potential for interaction of kava and St. John’s wort with drugs. J Ethnopharmacol 2005; 100(1-2):108-13.
37. Chan TY, Chan JC, Tomlinson B, et al. Chinese herbal medicines revisited: a Hong Kong perspective. Lancet 1993; 342(8886-8887):1532-4.
38. Kane JA, Kane SP, Jain S. Hepatitis induced by traditional Chinese herbs; possible toxic components. Gut 1995; 36(1):146-7.
39. Tomlinson B, Chan TY, Chan JC, et al. Herb-induced aconitine poisoning. Lancet 1993; 341(8841):370-1.
40. Melchart D, Linde K, Weidenhammer W, et al. Liver enzyme elevations in patients treated with traditional Chinese medicine. JAMA 1999; 282(1):28-9.
41. Graham-Brown R. Toxicity of Chinese herbal remedies. Lancet 1992; 340(8820):673-4.
42. Perharic-Walton L, Murray V. Toxicity of Chinese herbal remedies. Lancet 1992; 340(8820):674.
43. Yoshida EM, McLean CA, Cheng ES, et al. Chinese herbal medicine, fulminant hepatitis, and liver transplantation. Am J Gastroenterol 1996; 91(12):2647-8.
44. Ernst E. Adulteration of Chinese herbal medicines with synthetic drugs: a systematic review. J Intern Med 2002; 252(2):107-13.
45. Huang WF, Wen KC, Hsiao ML. Adulteration by synthetic therapeutic substances of traditional Chinese medicines in Taiwan. J Clin Pharmacol 1997; 37(4):344-50.
46. McRae CA, Agarwal K, Mutimer D, et al. Hepatitis associated with Chinese herbs. Eur J Gastroenterol Hepatol 2002; 14(5):559-62.
47. Nadir A, Agrawal S, King PD, et al. Acute hepatitis associated with the use of a Chinese herbal product, Ma-Huang. Am J Gastroenterol 1996; 91(7):1436-8.
48. Borum ML. Fulminant exacerbation of autoimmune hepatitis after the use of Ma Huang. Am J Gastroenterol 2001; 96(5):1654-5.
49. Nelson R. FDA issues alert on Ephedra supplements in the U.S.A. Lancet 2004; 363(9403):135.
50. Neff GW, Reddy R, Durazo FA, et al. Severe hepatotoxicity associated with the use of weight loss diet supplements containing Ma Huang or usnic acid. J Hepatol 2004; 41(6):1062-4.
51. But PP, Tomlinson B, Lee KL. Hepatitis related to the Chinese medicine Shou-Wu-Pian manufactured from Polygonum multiflorum. Vet Hum Toxicol 1996; 38(4):280-2.
52. Park GJ, Mann SP, Ngu MC. Acute hepatitis induced by Shou-Wu-Pian, a herbal product derived from Polygonum multiflorum. J Gastroenterol Hepatol 2001; 16(1):115-7.
53. Kao WF, Hung DZ, Tsai WJ, et al. Podophyllotoxin intoxication: toxic effect of Bajiaolian in herbal therapeutics. Hum Exp Toxicol 1992; 11(6):480-7.
54. Woolf GM, Petrovic LM, Rotjer SE, et al. Acute hepatitis associated with the Chinese herbal product Jin Bu Huan. Ann Intern Med 1994; 121(10):729-35.
55. Thomassen D, Slattery JT, Nelson SD. Menthofuran-dependent and independent aspects of pulegone hepatotoxicity: roles of glutathione. J Pharmacol Exp Ther 1990; 253(2):567-72.
56. Yeung CY. Neonatal hyperbilirubinemia in Chinese. Trop Geogr Med 1973; 25(2):151-7.
57. Horowitz RS, Dart RC, Gomez H, et al. Jin Bu Huan toxicity in children-Colorado, 1993. MMWR Morb Mortal Wkly Rep 1993; 42(33):633-5.
58. Horowitz RS, Feldhaus K, Dart RC, et al. The clinical spectrum of Jin Bu Huan toxicity. Arch Intern Med 1996; 156(8):899-903.
59. Lin TJ, Tsai MS, Chiou NM, et al. Hepatotoxicity caused by Breynia officinalis. Vet Hum Toxicol 2002; 44(2):87-8.
60. Lin TJ, Su CC, Lan CK, et al. Acute poisonings with Breynia officinalis-an outbreak of hepatotoxicity. J Toxicol Clin Toxicol 2003; 41(5):591-4.
61. Itoh S, Marutani K, Nishijima T, et al. Liver injuries induced by herbal medicine, syo-saiko-to (xiaochai- hu-tang). Dig Dis Sci 1995; 40(8):1845-8.
62. Yamashiki M, Nishimura A, Suzuki H, et al. Effects of the Japanese herbal medicine “Sho-saiko-to” (TJ-9) on in vitro interleukin-10 production by peripheral blood mononuclear cells of patients with chronic hepatitis C. Hepatology 1997; 25(6):1390-7.
63. Kamiyama T, Nouchi T, Kojima S, et al. Autoimmune hepatitis triggered by administration of an herbal medicine. Am J Gastroenterol 1997; 92(4):703-4.
64. Larrey D, Vial T, Pauwels A, et al. Hepatitis after germander (Teucrium chaemaedrys) administration:another instance of herbal medicine hepatotoxicity. Ann Intern Med 1992; 117(2):129-32.
65. Lekehal M, Pessayre D, Lereau JM, et al. Hepatotoxicity of the herbal medicine, germander. Metabolic activation of its furano dierpenoids by cytochrome P4503A depletes cytoskeletonassociated protein thiols and forms plasma membrane blebs in rat hepatocytes. Hepatology 1996; 24(1):212-8.
66. Loeper J, Descatoire V, Letteron P, et al. Hepatotoxicity of germander in mice. Gastroenterology 1994; 106(2):464-72.
67. Fau D, Lekehal M, Farrell G, et al. Diterpenoids from germander, an herbal medicine, induce apoptosis in isolated rat hepatocytes. Gastroenterology 1997; 113(4):1334-46.
68. De Berardinis V, Moulis C, Maurice M, et al. Human microsomal epoxide hydrolase is the target of germander-induced autoantibodies on the surface of human hepatocytes. Mol Pharmacol 2000; 58(3):542-51.
69. Mattei A, Rucay P, Samuel D, et al. Liver transplantation for severe acute liver failure after herbal medicine (Teucrium polium) administration. J Hepatol 1995; 22(5):597.
70. Dourakis SP, Papanikolaou IS, Tzemanakis EN, et al. Acute hepatitis associated with herb (Teucrium capitatum L.) administration. Eur J Gastroenterol Hepatol 2002; 14(6):693-5.
71. Anderson IB, Mullen WH, Mecker JE, et al. Pennyroyal toxicity: measurement of toxic metabolite levels in two cases and review of the literature. Ann Intern Med 1996; 124(8):726-34.
72. Madyastha KM, Raj CP. Biotransformations of R-(C)pulegone and menthofuran in vitro: chemical basis for toxicity. Biochem Biophys Res Commun 1990; 173(3):1086-92.
73. McClanahan RH, Thomassen D, Slattery JT, et al. Metabolic activation of (R)-(C)-pulegone to a reactive enonal that covalently binds to mouse liver proteins. Chem Res Toxicol 1989; 2(5):349-55.
74. Georgiou M, Sianidou L, Hatzis T, et al. Hepatotoxicity due to Atractylis gummifera-L. J Toxicol Clin Toxicol 1988; 26(7):487-93.
75. Hedili A, Warnet JM, Thevenin M, et al. Biochemical investigation of Atractylis gummifera-L hepatotoxicity in the rat. Arch Toxicol Suppl 1989; 13:312-5.
76. Stewart MJ, Steenkamp V. The biochemistry and toxicity of atractyloside: a review. Ther Drug Monit 2000; 22(6):641-9.
77. Mokhobo KP. Herb use and necrodegenerative hepatitis. S Afr Med J 1976; 50(28):1096-9.
78. Benninger J, Schneider HT, Schuppan D, et al. Acute hepatitis induced by greater celandine (Chelidonium majus). Gastroenterology 1999; 117(5):1234-7.
79. Favreau JT, Ryu ML, Braunstein G, et al. Severe hepatotoxicity associated with the dietary supplement LipoKinetix. Ann Intern Med 2002; 136(8):590-5.
80. Han D, Matsumaru K, Rettori D, et al. Usnic acid-induced necrosis of cultured mouse hepatocytes:inhibition of mitochondrial function and oxidative stress. Biochem Pharmacol 2004; 67(3):439-51.
81. Durazo FA, Lassman C, Han SH, et al. Fulminant liver failure due to usnic acid for weight loss. Am J Gastroenterol 2004; 99(5):950-2.
82. Whiting PW, Clouston A, Kerlin P. Black cohosh and other herbal remedies associated with acute hepatitis. Med J Aust 2002; 177(8):432-5.
83. Cohen SM, O’Connor AM, Hart J, et al. Autoimmune hepatitis associated with the use of black cohosh: a case study. Menopause 2004; 11(5):575-7.
84. Levitsky J, Alli TA, Wisecarver J, et al. Fulminant liver failure associated with the use of black cohosh. Dig Dis Sci 2005; 50(3):538-9.
85. Wang MY, West BJ, Jensen CJ, et al. Morinda citrifolia (Noni): a literature review and recent advances in Noni research. Acta Pharmacol Sin 2002; 23(12):1127-41.
86. Millonig G, Stadlmann S, Vogel W. Herbal hepatotoxicity: acute hepatitis caused by a Noni preparation (Morinda citrofolia). Eur J Gastroenterol Hepatol 2005; 17(4):445-7.
87. Stadlbauer V, Fickert P, Lackner C, et al. Hepatotoxicity of NONI juice: report of two cases. World J Gastroenterol 2005; 11(30):4758-60.
88. Hirono I, Kachi H, Kato T, et al. A survey of acute toxicity of cycads and mortality rate from cancer in the Miyako Islands Okinawa. Acta Pathol Jap 1970; 20(3):327-37.
89. Gloro R, Hourmand-Ollivier I, Mosq B, et al. Fulminant hepatitis during self-medication with hydroalcoholic extract of green tea. Gastroenterol Hepatol 2005; 17(10):1135-7.
90. Bonkovsky HL. Hepatotoxicity associated with supplements containing Chinese green tea (Camellia sinensis). Ann Intern Med 2006; 144(1):68-71.
91. Larson J, Vender R, Camuto P. Cholestatic jaundice due to ackee fruit poisoning. Am J Gastroenterol 1994; 89(9):1577-8.
92. Centers for Disease Control (CDC). Toxic hypoglycemic syndrome-Jamaica, 1989-1991. MMWR Morb Mortal Wkly Rep 1992; 41(4):53-5.
93. Sinniah R, Sinniah D, Chia LS, et al. Animal model of margosa oil ingestion with Reye-like syndrome. Pathogenesis of microvesicular fatty liver. J Pathol 1989; 159(3):255-64.
94. Sinniah D, Baskaran G. Margosa oil poisoning as a cause of Reye’s syndrome. Lancet 1981; 1(8218):487-9.
95. Schiano TD. Hepatotoxicity and complementary and alternative medicines. Clin Liver Dis 2003; 7(2):453-73.
96. Fraga CG, Oteiza PI. Iron toxicity and antioxidant nutrients. Toxicology 2002; 180(1):23-32.
97. Ramm GA, Ruddell RG. Hepatotoxicity of iron overload: mechanisms of iron-induced hepatic fibrogenesis. Semin Liver Dis 2005; 24(4):433-49.
98. Daram SR, Hayashi PH. Acute liver failure due to iron overdose in an adult. South Med J 2005; 98(2):241-4.
99. Krasinski SD, Cohn JS, Schaefer EJ, et al. Postprandial plasma retinyl ester response is greater in older subjects compared with younger subjects. J Clin Invest 1990; 85(3):883-92.
100. Allen LH, Haskell M. Estimating the potential for vitamin A toxicity in women and young children. J Nutr 2002; 132(Suppl. 9):2907S-19.
101. Myhre AM, Carlsen MH, Bøhn SK, et al. Water-miscible, emulsified, and solid forms of retinol supplements are more toxic than oil-based preparations. Am J Clin Nutr 2003; 78(6):1152-9.
102. Qian GS, Ross RK, Yu MC, et al. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People’s Republic of China. Cancer Epidemiol Biomarkers Prev 1994; 3(1):3-10.
103. Wang LY, Hatch M, Chen CJ, et al. Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan. Int J Cancer 1996; 67(5):620-5.
104. Henry SH, Bosch FX, Bowers JC. Aflatoxin, hepatitis and worldwide liver cancer risks. Adv Exp Med Biol 2002; 504:229-33.
105. Groisman IJ, Koshy R, Henkler F, et al. Downregulation of DNA excision repair by the hepatitis B virus-x protein occurs in p53-proficient and p53-deficient cells. Carcinogenesis 1999; 20(3):479-83.
106. Yu MC, Yuan JM. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 2004; 127(5 Suppl. 1):S72-8.
107. Das M, Khanna SK. Clinicoepimediological, toxicological, and safety evaluation studies on argemone oil. Crit Rev Toxicol 1997; 27(3):273-97.
108. Sharma BD, Bhatia V, Rahtee M, et al. Epidemic dropsy: observations on pathophysiology and clinical features during the Delhi epidemic of 1998. Trop Doct 2002; 32(2):70-5.
109. McElhiney J, Lawton LA. Detection of the cyanobacterial hepatotoxins microcystins. Toxicol Appl Pharmacol 2005; 203(3):219-30.
110. Azevedo SM, Carmichael WW, Jochimsen EM, et al. Human intoxication by microcystins during renal dialysis treatment in Caruaru-Brazil. Toxicology 2002; 181-182:441-6.
111. WHO. Guidelines for drinking-water quality. Addendum to Volume 2, Health Criteria and Other Supporting Information. 2nd ed. Geneva: World Health Organisation, 1998:93.
112. Bhattacharya R, Sugendran K, Dangi RS, et al. Toxicity evaluation of freshwater cyanobacterium Microcystis aeruginosa PCC 7806: II. Nephrotoxicity in rats. Biomed Environ Sci 1997; 10(1):93-101.
113. Yu SZ. Primary prevention of hepatocellular carcinoma. J Gastroenterol Hepatol 1995; 10(6):674-82.
114. David DB, Kirkby GR, Noble BA. Bacillus cereus endophthalmitis. Br J Ophthalmol 1994; 78(7):577-80.
115. Gaur AH, Patrick CC, McCullers JA, et al. Bacillus cereus bacteremia and meningitis in immunocompromised children. Clin Infect Dis 2001; 32(10):1456-62.
116. Dierick K, Van Coillie E, Swiecicka I, et al. Fatal family outbreak of Bacillus cereus-associated food poisoning. J Clin Microbiol 2005; 43(8):4277-9.
117. Mahler H, Pasi A, Kramer JM, et al. Fulminant liver failure in association with the emetic toxin of Bacillus cereus. N Engl J Med 1997; 336(16):1142-8.
118. Latsios G, Petrogiannopoulos C, Hartzoulakis G, et al. Liver abscess due to Bacillus cereus: a case report. Clin Microbiol Infect 2003; 9(12):1234-7.
119. Lin YF, Lin SH. Simultaneous acute renal and hepatic failure after ingesting raw carp gall bladder. Nephrol Dial Transplant 1999; 14(8):2011-2.
120. Fugh-Berman A. Herb-drug interaction. Lancet 2000; 355(9198):134-8.
121. Barone GW, Gurley BJ, Ketel BL, et al. Herbal supplements: a potential for drug interactions in transplant recipients. Transplantation 2001; 71(2):239-41.
122. Moore LB, Goodwin B, Jones SA, et al. St. John’s wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 2000; 97(13):7500-2.
123. Bailey DG, Arnold JMD, Spence JD. Grapefruit juice and drugs: how significant is the interaction? Clin Pharmacol 1994; 26(2):91-8.
124. Apitz-Castro R, Badimon JJ, Badimon L. Effect of ajoene, the major antiplatelet compound from garlic, on platelet thrombus formation. Thromb Res 1992; 68(2):145-55.
125. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs 2001; 61(15):2163-75.
126. Le Poncin Lafitte M, Rapin J, Rapin JR. Effects of Ginkgo Biloba on changes induced by quantitative cerebral microembolization in rats. Arch Int Pharmacodyn Ther 1980; 243(2):236-44.
127. Smith PF, Maclennan K, Darlington CL. The neuroprotective properties of the Ginkgo biloba leaf: a review of the possible relationship to platelet-activating factor (PAF). J Ethnopharmacol 1996; 50(3):131-9.
128. Backon J. Ginger as an antiemetic: possible side effects due to its thromboxane synthetase activity. Anaesthesia 1991; 46(8):705-6.
129. Park HJ, Lee JH, Song YB, et al. Effects of dietary supplementation of lipophilic fraction from Panax ginseng on cGMP and cAMP in rat platelets and on blood coagulation. Biol Pharm Bull 1996; 19(11):1434-9.
130. Miller LG. Herbal medicinals. Selected clinical considerations focusing on known or potential drug- herb interactions. Arch Intern Med 1998; 158(20):2200-11.
131. Homma M, Oka K, Ikeshima K, et al. Different effects of traditional Chinese medicines containing similar herbal constituents on prednisolone pharmacokinetics. J Pharm Pharmacol 1995; 47(8):687-92.
132. Karliova M, Treichel U, Malagò M, et al. Interaction of Hypericum perforatum (St. John’s wort) with cyclosporin a metabolism in a patient after liver transplantation. J Hepatol 2000; 33(5):853-5.
133. Schuppan D, Jia JD, Brinkhaus B, et al. Herbal products for liver diseases: a therapeutic challenge for the new millennium. Hepatology 1999; 30(4):1099-104.